NOAC 2015: What Have We Learned?
|
|
- Lorraine McCarthy
- 6 years ago
- Views:
Transcription
1 NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University
2 Disclosures Honoraria / Research Grants Abbott, Aegerion Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Miraculins, Novartis, NovoNordisk, Pfizer, Roche, Sanofi, Servier, Takeda Co-author and/or reviewer for 2010, 2012, 2014 CCS AF Guidelines
3 Key Lesson NOACs are preferred over warfarin
4 Warfarin in AF: High Efficacy Stroke Death 67% 26% Effect of VKA compared to placebo 1. Hart RG et al. Ann Intern Med. 2007;146: ; 2. CCS 2012 AF Guidelines Can J Cardiol. 2012; 28:
5 Using Warfarin Remains Challenging Only 55% of AF patients without contraindications receive warfarin *1 Mean TTR is low in patients receiving warfarin Rose et al (N=124,551) 2 58% Patients (%) (n=1064) (n=1596) (n=3707) (n=3752) (n=963) Age (y) 11,082 patients with nonvalvular atrial fibrillation 55% overall use 1 Baker et al (N=22,237) Rose et al (N=3104) Sarawate et al (N=470) McCormick et al (N=174) % 55% 51% 67% Mean TTR (%) 1. Go AS et al. Ann Intern Med. 1999;131(12): Rose AJ et al. Circ Cardiovasc Qual Outcomes. 2011;4(1): Baker WL et al. J Manag Care Pharm. 2009;15(3): Rose AJ et al. J Thromb Haemost. 2008;6(10): Sarawate C et al. J Thromb Thrombolysis. 2006;21(2): McCormick D et al. Arch Intern Med. 2001;161(20):
6 Warfarin use in general practice: Discontinuation Patients using warfarin (%) Years after starting treatment 6 Age yrs Age yrs Age yrs Age yrs Age yrs Age 85 + yrs Gallagher AM, et al. J Thromb Haemost 2008;6: HQ14NP
7 New Anticoagulants vs. Warfarin Stroke (ischemic or hemorrhagic) or Systemic Embolism Connolly SJ, et al. N Engl J Med 2009;361: Patel MR, et al. N Engl J Med 2011;365: Granger CB, et al. N Engl J Med 2011;365: Giugliano RP, et al. N Engl J Med 2013;369:
8 New Anticoagulants vs. Warfarin Major Bleeding Connolly SJ, et al. N Engl J Med 2009;361: Patel MR, et al. N Engl J Med 2011;365: Granger CB, et al. N Engl J Med 2011;365: Giugliano RP, et al. N Engl J Med 2013;369:
9 New Anticoagulants vs. Warfarin Intracranial Hemorrhage Connolly SJ, et al. N Engl J Med 2009;361: Patel MR, et al. N Engl J Med 2011;365: Granger CB, et al. N Engl J Med 2011;365: Giugliano RP, et al. N Engl J Med 2013;369:
10 New Anticoagulants vs. Warfarin Mortality Connolly SJ, et al. N Engl J Med 2009;361: Patel MR, et al. N Engl J Med 2011;365: Granger CB, et al. N Engl J Med 2011;365: Giugliano RP, et al. N Engl J Med 2013;369:
11 Canadian oral anticoagulant use for AF: Gradual increase in OAC use (thousands) Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Apr-14 May-14 Prescriptions NOAC (SPAF) Warfarin (50%) OAC (SPAF) NOAC, novel oral anticoagulant; OAC, oral anticoagulant; SPAF, stroke prevention in atrial fibrillation; SPAF Market = Warfarin at 50%, Xarelto 10 mg removed. Source: IMS GPM (May, 2014). 432HQ14NP
12 NOACs in 2015
13 Key Lessons How much AF is enough AF? Special populations Management of bleeding / reversal CCS guidelines 2014
14 How much atrial fibrillation is atrial fibrillation? Any arrhythmia that has the ECG characteristics of AF and lasts sufficiently long for a 12-lead ECG to be recorded, or at least 30 seconds on a rhythm strip, should be considered as AF Camm et al. European Heart Journal 2010:31;
15 Even short durations of AF are associated with an increased risk of stroke/se >24 hours: >6 hours: >6 minutes: Increased risk of stroke/se HR: 1.98 (CI , p=0.02) Increased risk of stroke/se HR 2.00 (CI , p=0.02) Increased risk of stroke/se HR 1.76 (CI , p=0.05) Healey et al. N Engl J Med 2012;366:120-9
16 ARTESiA: Design Pacemaker or implanted defibrillator CHA 2 DS 2 -VASC score >3 1 episode of SCAF lasting 6 minutes (and <24 hours) No history of clinical AF Apixaban 5 mg BD 2.5 mg BD in selected patients Double-blind R 3,719 patients ASA ( mg/day) Primary outcome: ischaemic stroke or SE SCAF, subclinical atrial fibrillation. Clinicaltrials.gov identifier: NCT HQ14NP
17 Key Lessons How much AF is enough AF? Special populations Management of bleeding / reversal CCS guidelines 2014
18 Stroke and Bleeding in AF Patients With Moderate CKD (Stage 3) Aspirin-treated patients with Stage 3 CKD vs. egfr 60 ml/min AVERROES Trial Outcome egfr 60 Stage 3 CKD ml/min %/y HR (95%CI) Stroke / SE ( ) Major bleeding All-cause mortality ( ) ( ) Hart RG, et al. Presented at AHA Scientific Sessions, 2011.
19 Efficacy and safety of NOACs versus warfarin when egfr is 50mL/min Dabigatran 110 mg Dabigatran 150 mg Rivaroxaban Apixaban HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) Stroke or SE 0.77 ( ) 0.54 ( ) 0.84 ( ) 0.79 ( ) Major bleeding 0.98 ( ) 1.01 ( ) 0.95 ( ) 0.50 ( )* Favours Favours Favours Favours Favours Favours Favours Favours dabigatran warfarin dabigatran warfarin rivaroxaban warfarin apixaban warfarin Head-to-head studies do not exist, and direct comparisons between agents may not be made *p for interaction = egfr, estimated glomerular filtration rate. Extracted from: Capranzano P, et al. Expert Rev Cardiovasc Ther 2013;11:
20 Efficacy and safety of NOACs versus warfarin in the 75 age group Dabigatran 110 mg Dabigatran 150 mg Rivaroxaban Apixaban HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) Stroke or SE 0.88 ( ) 0.67 ( ) 0.80 ( ) 0.71 ( ) Major bleeding 1.01 ( )* 1.18 ( )* 1.11 ( ) 0.63 ( ) ICH 0.37 ( ) 0.42 ( ) 0.80 ( ) 0.33 ( ) Favours Favours Favours Favours Favours Favours Favours Favours dabigatran warfarin dabigatran warfarin rivaroxaban warfarin apixaban warfarin Head-to-head studies do not exist, and direct comparisons between agents may not be made * Significant interaction p< ICH, intracranial haemorrhage. Extracted from: Capranzano P, et al. Expert Rev Cardiovasc Ther 2013;11:
21 NOACs and renal function All 3 agents are partly excreted by kidney (unlike warfarin) This is particularly true for dabigatran (80%) No new agent should be used for CrCl < (warfarin) Rivaroxaban 15 mg od may be used for CrCl 30-50, Apixaban 2.5 mg bid for increased bleeding risk Renal function should be monitored periodically in all patients receiving new agents (Q6-12 months and with acute illness)
22 Key Lessons How much AF is enough AF? Special populations Management of bleeding / reversal CCS guidelines 2014
23 NOAC bleeding management strategies are similar to those for VKAs Bleeding while using a NOAC Mild bleeding Moderate/severe bleeding Life-threatening bleeding Delay next dose or discontinue Reconsider concomitant medication + Supportive measures Mechanical compression Surgical haemostasis Fluid replacement (colloids if needed) RBC substitution if needed Fresh frozen plasma (as plasma expander) Platelet substitution (if platelet count /L) + Consider PCC 25 U/kg; repeat 1 /2 if indicated apcc 50I E/kg; max 200 IE/kg/day rfviia 90 µg/kg Additional options for dabigatran Maintain adequate diuresis Consider haemodialysis apcc = activated prothrombin complex concentrates; PCC = prothrombin complex concentrates; rfviia = recombinant Factor VIIa Adapted from Heidbuchel H et al. Europace 2013;15:625 51
24 Assessing coagulation status with NOACs for specific situations Test Dabigatran Rivaroxaban Apixaban Specific HEMOCLOT Anti-Xa Anti-Xa aptt Nonspecific PT TT No effect No effect PT = prothrombin time; TT = thrombin time Personal communication John Eikelboom
25 Apixaban and dabigatran: 30-Day Mortality Rate after a Major Bleed Apixaban - ARISTOTLE Mortality (%) 0.2 Major ECH associated with apixaban led to less hospitalization or intervention Dabigatran Pooled analysis Mortality (%) 30-day mortality for treatment groups combined HR=0.50; 95% CI Warfarin 0.1 aor=0.56; 95% CI ; p=0.009 Warfarin Apixaban Dabigatran (combined) Months since first dose Time (days) ECH, extracranial haemorrhage Hylek et al. JACC 2014;63: Majeed A et al. Circulation 2013;128:
26 Specific reversal agents in development for novel oral anticoagulants Company Portola Pharmaceuticals Boehringer Ingelheim Compound Reversal for: Status PRT064445/ (andexanet alfa) BI (idarucizumab) Factor Xa inhibitor Universal No Factor IIa inhibitor No Specific for dabigatran LMWH/ fondaparinux Yes (antithrombinmediated Factor Xa inhibition) Perosphere, Inc. PER977 Universal Universal Universal No Phase II ongoing; 1 phase III started (apixaban/ rivaroxaban); 2 planned (edoxaban) 2 Phase I completed; 3 phase III started 4 Phase I completed 5 1. clinicaltrials.gov, NCT ; 2. Portola Pharmaceuticals, 2014; 3. clinicaltrials.gov NCT ; 4. clinicaltrials.gov, NCT ; 5. clinicaltrials.gov, NCT
27 Procedural Bleeding Risks LOW (2-DAY RISK OF MAJOR BLEED 0% 2%) Cholecystectomy Abdominal hysterectomy GI endoscopy +- biopsy Pacemaker/defibrillator insertion Simple dental extractions Knee/hip replacement and shoulder/foot/hand surgery Dilatation and curettage Skin cancer excision Hemorrhoid surgery Cataract/no cataract eye surgery HIGH (2-DAY RISK OF MAJOR BLEED 2% 4%) Heart valve replacement Coronary artery bypass Abdominal aortic aneurysm repair Neurosurgical/urologic/head and neck/abdominal/breast cancer surgery) Bilateral knee replacement Transurethral prostate resection Kidney biopsy Vascular and general surgery Any major operation Spyropoulos AC & Doukatis JD. Blood. 2012; 120(15): Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution 28
28 A guidelines based approach to AF management Days of withdrawal prior to high bleeding risk procedure egfr ml/min/m 2 apixaban dabigatran rivaroxaban < 30* Focused Update CCS AF Guidelines Can J Cardiol (in press) Atrial Fibrillation Guidelines
29 Key Lessons How much AF is enough AF? Special populations Management of bleeding / reversal CCS guidelines 2014
30 Comparison of SPRINT-AF (Phase 1) to major OAC registries and RCT s Clinical factor SPRINT-AF* RE-LY ROCKET-AF ARISTOTLE ORBIT-AF Male 62.1% 63.6% 60.3% 64.7% 57% Age 75.7(67.5, 83) 71.5 ± (65, 78) 70 (63, 76) 75 (68, 82) Hypertension 73.6% 78.9% 90.5% 87.4% 85% Diabetes 29.7% 23.3% 39.9% 24.9% 30% Stroke or TIA 15% 20.0% 54.8% 19.4% 8.5% HF 18.8% 32.0% 62.5% 35.5% 34% Previous MI 16.2% 16.6% 17.3% 14.2% 14.3% Non-Paroxysmal AF 70.3% 67.2% 82.1% 84.7% 50% CHADS % 68.1% 100% 66.0% 75% GFR (ml/min/m 2 ) 64 (56, 80) - 67 (52, 86) - 70 (51, 97) Antiplatelet use 27% 39.7% 36.5% 32.8% 34.6% PPI use 26.6% 13.8% - - -
31 SPRINT-AF: Agreement of between clinician-reported and calculated CHADS 2, CHADS 2 - VASC, and HAS-BLED scores Clinician-reported risk vs. Weighed Kappa (95% CI) CHADS (95% CI: 0.35, 0.50) CHADS 2 - VASC 0.21 (95% CI: 0.15, 0.28) HAS-BLED 0.14 (95% CI: 0.07, 0.21) CHADS 2 (amongst clinicians who assess risk with CHADS 2 ) HAS-BLED (amongst clinicians who assess risk with HAS-BLED) 0.45 (95% CI: 0.36, 0.54) 0.11 (95% CI: 0.01, 0.27)
32 The CCS Algorithm for OAC Therapy in AF Age 65 YES OAC* NO Prior Stroke/SE/TIA or Hypertension or Heart failure or Diabetes Mellitus (CHADS 2 risk factors) YES OAC* Consider and modify (if possible) all factors influencing risk of bleeding on OAC (hypertension, antiplatelet drugs, NSAIDs, excessive alcohol, labile INRs) and specifically bleeding risks for NOACs (low egfr, age 75, low body weight)** NO **may require lower dosing CAD or Arterial vascular disease YES ASA (coronary, aortic, peripheral) NO No Antithrombotic We suggest that a NOAC be used in preference to warfarin for non-valvular AF. Atrial Fibrillation Guidelines
33 Summary of Key Lessons Patients > 65y and those with any CHADS risk factor should receive OAC. NOACs are generally preferred over warfarin. Stroke risk is increased with as little as 6 mins of AF whether patients with short AF duration deserve OAC is being studied. NOAC s have consistent efficacy and safety in CKD and in those > 75 y Bleeding on NOACs should be managed as per standard care mortality following a major bleed is lower on NOAC vs. warfarin. Specific antidotes are in development.
A Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationPRACTICAL MANAGEMENT OF NOAC s December 8,
PRACTICAL MANAGEMENT OF NOAC s December 8, 2017 1 Faculty Disclosure Faculty: John Eikelboom MBBS, MSc, FRCPC Jack Hirsh/PHRI Chair in Thrombosis and Atherosclerosis Career Award, Heart and Stroke Foundation
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationManaging Bleeding on NOACs
Managing Bleeding on NOACs and Other Evolving ED Protocols Objectives Understand that NOACs are widely used in clinical practice Discuss the new and evolving protocols for managing bleeding in patients
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationThrombosis Canada Clinical Tools. Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation
Thrombosis Canada Clinical Tools Perioperative Management of Anticoagulants Antithrombotic Use in Atrial Fibrillation Dr. Benjamin Bell, MD FRCPC Staff General Internist North York General Hospital Lecturer,
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationDr Calum Young Cardiologist Tauranga
Dr Calum Young Cardiologist Tauranga 8:30-9:25 WS #93: New Oral Anticoagulant Drugs and Management of AF 9:35-10:30 WS #105: New Oral Anticoagulant Drugs and Management of AF (Repeated) GPCME 2016: Anticoagulation
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationNew Oral Anticoagulants in Everyday Practice: Addressing Common Clinical Scenarios and Questions not covered by the big trials
New Oral Anticoagulants in Everyday Practice: Addressing Common Clinical Scenarios and Questions not covered by the big trials James Douketis, MD, FRCPC Specialty: Internal Medicine Professor, Department
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationStroke prevention, Clinical trials
Received: 13 May 2016 Revised: 8 August 2016 Accepted: 18 August 2016 DOI 10.1002/clc.22596 REVIEWS Special considerations for therapeutic choice of non vitamin K antagonist oral anticoagulants for Japanese
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationNovel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationReversal Agents and Peri-procedural Management
Contemporary Approach to Anticoagulation Management Reversal Agents and Peri-procedural Management Alawi A. Alsheikh-Ali, MD, MSc College of Medicine Mohammed Bin Rashid University of Medicine and Health
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationUse of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist?
Use of anticoagulants in AF patients with renal impairment What is the point of view of a cardiologist? Prof. Dan Atar, MD Dept. of Cardiology B Oslo University Hospital, Norway Vice-President of the ESC
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical University
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices Faculty John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationClo$ng vs bleeding: not as simple as we would like. OACs for stroke preven:on: Too many choices?
Clo$ng vs bleeding: not as simple as we would like OACs for stroke preven:on: Too many choices? Paul Dorian University of Toronto St Michael s Hospital . Speaker Disclosure Form Paul Dorian Disclosures:
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationΕπιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική;
2ο ΣΥΝΕΔΡΙΟ ΚΑΡΔΙΑΓΓΕΙΑΚΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΑΘΗΝΑ 2017 Επιλέγοντας NOACs. Επηρεάζουν την απόφασή μας τα δεδομένα από την καθημερινή κλινική πρακτική; Κωνσταντίνος Π. Λέτσας, MD, FEHRA Β Καρδιολογική Κλινική
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationBoehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017
Boehringer-Ingelheim satellite symposium Ligue cardiologique belge 13/05/2017 Dr André Peeters Service de Neurologie Cliniques Universitaires Saint-Luc / U.C.L. 1200 BRUXELLES Introduction 1. Aim NOACS
More information